Niche Hong Kong Stocks Navigate Policy Shifts Through Beauty, Project Management, and Control Transfers

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Hong Kong's niche stocks are navigating a shifting landscape as policy tailwinds and strategic pivots create pockets of resilience. Sihuan Pharmaceutical (0460.HK) has transformed its revenue mix with medical aesthetics now accounting for over half of sales, driving a 119% year-on-year net profit surge in the first half of 2026. Greentown Management Holdings (9979.HK) capitalized on relaxed property policies, expanding its project management pipeline with 34.1 billion yuan in new fees while maintaining 76.5% exposure to top-tier cities.

Meanwhile, control shifts are reshaping corporate trajectories. Twintek Investment Holdings (6182.HK) saw its controlling shareholder exit entirely in early September, while China Star Entertainment (0326.HK) experienced a 14% stake transfer that maintained majority control. SWHYHK (0218.HK) remains active in cross-border capital markets as joint sponsor for multiple IPO filings, including Ousutong's AI-driven compliance platform.

Operational adjustments are yielding mixed results: Jufutang Biotech (8217.HK) turned profitable through investment gains despite construction sector weakness, while Herbs Generation Group (2593.HK) narrowed losses by cutting marketing spend. Hang Lung Properties (0010.HK) advances its sustainability agenda with full renewable energy coverage across mainland assets by October, signaling long-term positioning amid volatile market conditions.

Source: Global Report The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.